Is vaccine response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?

Conclusions
Despite a primary vaccination performed before the first anti-CD20 cycle, our results suggest weaker immune responses at 6 and 12 months and decreased booster efficacy after introducing anti-CD20. Patients vaccinated prior to anti-CD20 introduction might falsely be considered as fully protected by vaccination.

Source: Journal of Neurology, Neurosurgery and Psychiatry - December 14, 2023 Category: Neurosurgery Authors: Jeantin, L., Abdi, B., Soulie, C., Sterlin, D., Maillart, E., Beigneux, Y., Hippolyte, A., Belin, L., Marcelin, A.-G., Pourcher, V., Louapre, C. Tags: COVID-19 Multiple sclerosis Source Type: research